Sirtex Medical announces collaboration with MIM Software


sirtexSirtex Medical has announced a collaboration with MIM Software. Under the terms of the agreement, Sirtex’s sales teams in the USA, Europe, and other key global markets will offer MIM SurePlan LiverY90 software alongside the company’s SIR-Spheres Y-90 resin microspheres to improve treatment precision for patients with hepatic tumours.

According to a company press release, MIM SurePlan LiverY90 provides timesaving tools and post-treatment dosimetry for interventional radiologists and nuclear medicine physicians treating hepatic tumours with SIR-Spheres. The software allows physicians to calculate the dose delivered by the microspheres to improve treatment decisions and patient care. The technology also incorporates CT, PET, SPECT and MRI scans simultaneously to deliver results on spheres deposition, coverage, and absorbed dose.

“Given the overlap of their technology and our SIR-Spheres product, Sirtex and MIM have a long history of working alongside clinical care teams,” comments Kevin Smith, Chief Executive Officer of Sirtex. “Now as partners, we will be able to combine our expertise and resources to provide an even higher level of support to treat liver tumours. We are excited to see how this collaboration will benefit physicians and ultimately improve treatment outcomes for patients.”

“We are proud and excited to partner with Sirtex, mainly because it will provide access to personalised dosimetry for a large number of patients across the globe,” says Andrew Nelson, Chief Executive Officer of MIM Software. “The treatment of liver tumours requires a multi-disciplinary approach, so it is a natural evolution for companies like ours to partner to provide an even faster, higher level of support and resources to treatment teams.”

In the USA, SIR-Spheres Y-90 resin microspheres received Premarket Approval (PMA) from the US Food and Drug Administration (FDA) and are indicated for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union, Argentina, Brazil, Canada, and several countries in Asia, such as India and Singapore.


Please enter your comment!
Please enter your name here